News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
Novo Nordisk (NYSE: NVO) severed its partnership with Hims & Hers (NYSE: HIMS), arguing that the company breached the ...
2don MSN
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
Shares of Hims & Hers Health (NYSE: HIMS) are imploding on Monday, down 32% as of 3:03 p.m. ET. The drop comes as the S&P 500 ...
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...
Hims & Hers Health, Inc. sees 38% YoY subscriber growth, driven by 70% choosing personalized treatments. Click for my updated ...
Zacks Investment Research on MSN23h
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should KnowHims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback